Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective study, researchers observed that additional rounds of intravenous corticosteroid pulse therapy led to only partial hair regrowth in some rapidly progressive alopecia areata cases, with all participants experiencing relapse, indicating limited efficacy for severe cases resistant to initial treatment.

This study reviews potential immune targets within hair follicles in alopecia areata, suggesting they may be associated with keratinocytes or melanocytes, and notes possible induction triggers like viruses and infections.

Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.

Botulinum A toxin injections reduced pain and promoted hair regrowth in a woman with a rare form of alopecia areata.

This study found that human hematopoietic mesenchymal stem cells increased the viability and migration of human outer root sheath cells in an in vitro alopecia areata model, involving Wnt/β-catenin and JAK/STAT pathways.

This review discusses treatment strategies for alopecia areata and emphasizes the importance of primary care physicians recognizing and managing the condition, with referrals to dermatologists for more severe cases.

In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.

This study concluded that both DPCP alone and combined with PRP are effective and safe for treating severe alopecia areata, with no significant difference between the two treatment methods.

In this study, two patients with severe alopecia areata who did not respond well to oral tofacitinib showed more than 50% hair regrowth after a single dose of intramuscular triamcinolone acetonide.

This narrative review found that ritlecitinib shows consistent effectiveness and a favorable safety profile for treating alopecia areata in clinical trials and real-world settings, with progressive hair regrowth observed, particularly when treatment is initiated early and maintained appropriately.

This paper reviews existing and emerging therapies for alopecia areata, describing the impact of targeted treatments in this field, and introduces a global network of disease registers to study the long-term safety and effectiveness of these new options.

This study found that adipose-derived stem cells with DKK1 knocked out using CRISPR/Cas9 promoted hair growth in an alopecia areata model more effectively than untreated stem cells, suggesting DKK1 is a potential therapeutic target for this condition.

This review concluded that botulinum toxins have various potential off-label uses for dermatological conditions, but further research is needed to fully establish their efficacy and safety in these applications.

This review suggests that the Mediterranean diet, protein-rich diets, and soy may support hair health in nonscarring alopecias like androgenetic alopecia.

This study found that corticosteroid pulse therapy may be more effective than oral cyclosporine with corticosteroid for patients with severe alopecia areata, especially for those with the plurifocal type or a short disease duration.

This review discusses the role of cutaneous and intestinal microbiota in the development of alopecia areata, summarizing current literature without reporting new clinical results.

This study found that individuals with androgenic alopecia had higher levels of vitamin D compared to those with telogen effluvium and healthy controls.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

This review provides a detailed overview of the causes, prevalence, pathophysiology, clinical presentation, and treatment of beard alopecia, highlighting conditions such as alopecia areata, pseudofolliculitis barbae, and tinea barbae, and aims to serve as a resource for clinicians handling such cases.

This review discusses the role of the complement pathway in alopecia areata and reports no new clinical results; the authors suggest that targeting this pathway could offer treatment options.

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

In this update, researchers incorporated TGA-approved Janus Kinase inhibitors into the Australian treatment guidelines for chronic, moderate to severe Alopecia areata, aiming to enhance recommended therapies by providing guidance on the use and management of these systemic medications.

In this study, ritlecitinib treatment for 12 and 24 weeks downregulated immunity-related genes and upregulated hair keratin genes in patients with alopecia areata, correlating with scalp hair regrowth response.

This review discusses the use of botulinum toxin for hair and scalp disorders and reports mixed findings, with most studies showing mild or non-significant effects on hair growth.

This study observed that intradermal injections of Betamethasone were more effective than topical Clobetazole for treating alopecia areata in children, while Tofacitinib showed higher efficacy in those with atopic dermatitis.

This study found that CRP levels were elevated in alopecia areata patients, with an inverse linear association between serum vitamin D and CRP levels specifically noted in ophiasis AA.

This chapter discusses the potential therapeutic applications of Botulinum toxin for various non-cosmetic skin conditions, such as acne, rosacea, and hyperhidrosis, highlighting case reports and some randomized controlled trials that indicate promise in alleviating discomfort, inflammation, and excessive sweating.

This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.

JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.